Cytek Biosciences (CTKB) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed QuidelOrtho (QDEL) over the past year, gaining 40.9% versus a loss of 55.6%. Over five years, CTKB leads with a -77.8% price change compared with -90.4% for QDEL. QuidelOrtho is the larger company by market cap ($851.0 million vs $699.3 million), about 1.2 times the size.
On valuation, QuidelOrtho trades at a lower forward P/E (8.6x vs 76.9x for Cytek Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | QDEL |
|---|---|---|
| Share price | $5.38 | $12.41 |
| Market cap | $699.31M | $851.02M |
| 1-day change | +0.75% | +0.81% |
| YTD return | +5.74% | -56.90% |
| 1-year return | +40.90% | -55.58% |
| 5-year return | -77.81% | -90.40% |
| Forward P/E | 76.86 | 8.61 |
| EPS (TTM) | $-0.62 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $35.58 |
| 52-week low | $3.31 | $9.92 |
| Distance from 52-week high | -13.37% | -65.12% |
| Analyst consensus | none | hold |
| Avg. price target upside | +3.35% | +18.21% |
| Average volume | 1.04M | 1.49M |
| Shares outstanding | 129.98M | 68.58M |
| Employees | 682 | 6,500 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTKB has outperformed QDEL by 96.5 percentage points over the past year.
- The two companies sit in different sectors: Cytek Biosciences in Industrials and QuidelOrtho in Health Care.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
CTKB vs QDEL FAQ
Which is bigger, Cytek Biosciences or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $851.02M compared with $699.31M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, CTKB or QDEL?
CTKB returned +40.90% over the past 12 months, compared with -55.58% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and QuidelOrtho in the same industry?
No. Cytek Biosciences is in the Industrials sector, while QuidelOrtho is in Health Care.